This phase I open-label dose-finding study will evaluate the safety, tolerability, and immunogenicity of a Sars-Cov-2 RNA vaccine candidate against COVID-19 in healthy 12-year-old children.
Investigator: Klein, Nicola
Funder: Pfizer Inc.
Explore all studies and publications
Division of Research
Oakland, CA 94612
Follow us on these external social media sites that will open in a new browser window.
© 2023 Kaiser Permanente Division of Research